# OnCo record leap-002 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/leap-002/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "leap-002", "NCT03713593" ;
  schema:name "LEAP-002"@en ;
  schema:description "LEAP-002 randomised 794 patients with untreated advanced liver cancer to lenvatinib with or without pembrolizumab. Adding the immunotherapy did not lengthen life beyond lenvatinib alone, partly because the control arm did unusually well, a reminder that not every immunotherapy plus anti-angiogenic pairing works."@en ;
  schema:url <https://onco.cc/trials/leap-002/> ;
  schema:dateModified "2026-09-07"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT03713593> ;
  onco:status "negative" ;
  onco:tag "failure", "lesson:control-arm" ;
  onco:phase "3" ;
  schema:startDate "2018-12-31" ;
  onco:cancers <https://onco.cc/cancers/hcc/> ;
  onco:technologies <https://onco.cc/technologies/antiangiogenic/>, <https://onco.cc/technologies/kinase-inhibitors/> ;
  onco:drugs <https://onco.cc/drugs/lenvatinib/>, <https://onco.cc/drugs/pembrolizumab/> ;
  onco:companies <https://onco.cc/companies/eisai/> .